A number of other research firms have also recently commented on PRGO. Jefferies Group set a $71.00 price target on shares of Perrigo and gave the company a hold rating in a report on Sunday, October 29th. Argus upgraded shares of Perrigo from a hold rating to a buy rating and set a $93.00 price target on the stock in a report on Friday, December 8th. UBS reiterated a buy rating and set a $98.00 price target (up previously from $84.00) on shares of Perrigo in a report on Thursday, October 5th. Oppenheimer initiated coverage on shares of Perrigo in a report on Thursday, September 7th. They set an outperform rating and a $88.00 price target on the stock. Finally, BidaskClub upgraded shares of Perrigo from a sell rating to a hold rating in a report on Saturday, September 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $92.13.
Shares of Perrigo (NYSE:PRGO) opened at $85.92 on Friday. Perrigo has a fifty-two week low of $63.68 and a fifty-two week high of $91.73. The company has a current ratio of 1.72, a quick ratio of 1.24 and a debt-to-equity ratio of 0.54. The company has a market cap of $12,055.96, a P/E ratio of 17.47, a PEG ratio of 1.82 and a beta of 0.70.
Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.39 EPS for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.28. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company posted $1.65 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. sell-side analysts forecast that Perrigo will post 4.88 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 19th. Investors of record on Friday, December 1st will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.74%. The ex-dividend date is Thursday, November 30th. Perrigo’s dividend payout ratio is currently -6.99%.
In related news, EVP John Wesolowski sold 388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $87.20, for a total value of $33,833.60. Following the sale, the executive vice president now owns 248 shares in the company, valued at $21,625.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 1,051 shares of company stock worth $89,810 in the last 90 days. 6.90% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Allen Investment Management LLC boosted its stake in shares of Perrigo by 7.1% during the 2nd quarter. Allen Investment Management LLC now owns 7,143 shares of the company’s stock worth $539,000 after acquiring an additional 473 shares during the last quarter. State Street Corp boosted its stake in shares of Perrigo by 1.7% during the 2nd quarter. State Street Corp now owns 6,757,086 shares of the company’s stock worth $510,294,000 after acquiring an additional 112,287 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Perrigo by 7.5% during the 3rd quarter. Sei Investments Co. now owns 131,284 shares of the company’s stock worth $11,114,000 after acquiring an additional 9,192 shares during the last quarter. Andra AP fonden boosted its stake in shares of Perrigo by 9.9% during the 3rd quarter. Andra AP fonden now owns 16,700 shares of the company’s stock worth $1,414,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Monetta Financial Services Inc. purchased a new position in shares of Perrigo during the 2nd quarter worth $755,000. Institutional investors and hedge funds own 85.53% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.